Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M19,580Revenue (TTM) $M11,937Net Margin (%)7.3Altman Z-Score1.3
Enterprise Value $M33,580EPS (TTM) $1.6Operating Margin %11.2Piotroski F-Score6
P/E(ttm)22.4Beneish M-Score-2.6Pre-tax Margin (%)6.7Higher ROA y-yY
Price/Book1.510-y EBITDA Growth Rate %9.6Quick Ratio1.0Cash flow > EarningsY
Price/Sales1.65-y EBITDA Growth Rate %4.2Current Ratio1.5Lower Leverage y-yY
Price/Free Cash Flow22.0y-y EBITDA Growth Rate %58.0ROA % (ttm)2.5Higher Current Ratio y-yY
Dividend Yield %--PEG5.5ROE % (ttm)7.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M536ROIC % (ttm)5.2Gross Margin Increase y-yN

Gurus Latest Trades with MYL

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

MYL is held by these investors:



MYL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Malik RajivPresident 2017-06-09Sell25,000$40-6.02view
Mauro AnthonyChief Commercial Officer 2017-06-09Sell10,000$40-6.02view
ABBOTT LABORATORIES10% Owner 2017-03-23Sell44,000,000$41.6-9.64view
BRESCH HEATHER MCEO 2016-08-09Sell100,200$50-24.82view
MAROON JOSEPH C MDDirector 2016-06-03Buy1,670$44.95-16.37view
MAROON JOSEPH C MDDirector 2016-05-25Buy2,370$42.47-11.49view
Cindrich Robert JDirector 2016-05-25Buy1,190$42.47-11.49view
HIGGINS MELINA EDirector 2016-05-12Buy19,900$38.68-2.82view
HIGGINS MELINA EDirector 2016-05-06Buy100$38.69-2.84view
HIGGINS MELINA EDirector 2016-04-28Buy35,000$42.92-12.42view

Press Releases about MYL :

Quarterly/Annual Reports about MYL:

News about MYL:

Articles On GuruFocus.com
Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adult Nov 13 2017 
Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adult Nov 13 2017 
Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange (TASE) Nov 10 2017 
Mylan Launches Generic Clolar® for Injection Nov 09 2017 
New Research Coverage Highlights Mylan, Genworth Financial, Chevron, Southern Company, ConocoPhillip Nov 02 2017 
Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Nov 01 2017 
Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Nov 01 2017 
Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar Nov 01 2017 
Mylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint Oct 31 2017 
Mylan's EpiPen4Schools® Program Surpasses One Million Free Epinephrine Auto-Injector Donations to U Oct 27 2017 

More From Our Partners
Theravance Shares Rise on Approval of Glaxo's COPD Therapy Nov 17 2017 - ZACKS
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK